Methods for determining risk of developing cervical cancer

Abstract

The present invention relates generally to a method of identifying a subject having an increased risk of developing cervical cancer based on levels of IGF-II in serum and levels of EGF-R and HPV-E6/E7 in cervical epithelial cells and in serum.

1 . A method of determining whether a subject has an increased risk of developing cervical cancer, comprising determining the amount of human papilloma virus (HPV)-E6/E7 in a sample of cervical epithelial cells from the subject whereby the amount of HPV-E6/E7 greater than 54% above normal control value in the sample indicates that the subject has an increased risk of developing cervical cancer.  
     
     
         2 . The method of  claim 1 , wherein the subject has previously been identified as having cervical intraepithelial neoplasia (CIN).  
     
     
         3 . A method of determining whether a subject has an increased risk of developing cervical cancer, comprising determining the amount of epidermal growth factor receptor (EGF-R) in a sample of cervical epithelial cells from the subject, whereby the amount of EFG-R greater than 51% above normal control value in the sample indicates that the subject has an increased risk of developing cervical cancer.  
     
     
         4 . The method of  claim 3 , wherein the subject has previously been identified as having cervical intraepithelial neoplasia (CIN).  
     
     
         5 . A method of assessing the efficacy of a treatment for cervical cancer in a subject, comprising determining the amount of human papilloma virus (HPV)-E6/E7 in a sample of cervical epithelial cells from the subject whereby the amount of HPV-E6/E7 less than 54% above normal control value in the sample indicates that the treatment for cervical cancer has been efficacious.  
     
     
         6 . A method of assessing the efficacy of a treatment for cervical cancer in a subject, comprising determining the amount of epidermal growth factor receptor (EGF-R) in a sample of cervical epithelial cells from the subject, whereby the amount of EFG-R less than 51% above normal control value in the sample indicates that the treatment for cervical cancer has been efficacious.